Masonic Cancer Center, University of Minnesota
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Masonic Cancer Center, University of Minnesota sits in the top decile of US sponsors by registered trial count (#132 of 15,742 sponsors by registered trial count).
Masonic Cancer Center, University of Minnesota: 249 sponsored US clinical trials, 36 recruiting.
Masonic Cancer Center, University of Minnesota sponsors 249 registered US clinical trials on ClinicalTrials.gov, 36 of them currently recruiting, and 127 completed. 1 of these trials are in Phase 3-4 (later-stage) and 183 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 7 trials.
Top-decile sponsor footprint
Masonic Cancer Center, University of Minnesota ranks in the top decile of sponsors by registered trial count (#132 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
127 of 201 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
249 total, page 1 of 5
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
NCT07591649
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
NCT07560865
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
NCT07493538
GTB-5550 in Advanced Solid Tumors
NCT07541573
Rural Smoking Cessation
NCT06584929
LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorectal Cancer
NCT07153016
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
NCT06792825
UNTOLD Ovarian Cancer Unmet Needs Survey
NCT07070726
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
NCT07008638
American Indian Smokefree Native RCT
NCT06544811
Trial of Cell Based Therapy for DMD
NCT06692426
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
NCT05025774
Adenovirus (RGDCRAdCOX2F)
NCT06693986
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
NCT06377540
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
NCT06594445
Allo HSCT for High Risk Hemoglobinopathies
NCT06872333
Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures
NCT06295757
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT06342986
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
NCT06412497
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
NCT06414278
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
NCT06411795
Study of PAT in Patients With Solid Tumor Cancers
NCT05338658
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
NCT05735717
Allo HSCT Using RIC and PTCy for Hematological Diseases
NCT05805605
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
NCT04105270
Role of Acetaldehyde in the Development of Oral Cancer
NCT05973656
Observational Study of Exposure to Environmental Toxicants Among Firefighters
NCT05643014
Adrenoleukodystrophy National Registry Study
NCT03789721
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT03579875
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03314974
Auto Stem Cell Transplant for Lymphoma Patients
NCT03125642
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
NCT01962636
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
NCT02605421
Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
NCT02161783
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
NCT01666080
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
NCT01451502
Assessing the Time Demands of Cancer
NCT05708703
Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors
NCT05665543
Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
NCT05634512
NF-1, Nutraceutical Intervention
NCT05363267
Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users
NCT04003805
Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure
NCT03998735
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
NCT04514029
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
NCT03934840
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
NCT03674411
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
NCT03642626
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
NCT02171104
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
NCT01652092
Remote Trial - Tobacco Product Standard (VLNC)
NCT06442384
Feasibility Study - Filter Ventilation
NCT04514471
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 76 |
| Phase 2 | 107 |
| Phase 3 | 1 |
What is open in the Masonic Cancer Center, University of Minnesota pipeline
36 recruiting of 249 indexed (14% open); 127 completed (51%).
Phase mix: 1 late (III/IV) vs 183 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Masonic Cancer Center, University of Minnesota: open-pipeline peers nationwide
Peers matched on 249 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Masonic Cancer Center, University of Minnesota sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 249 trials (± recruiting share)
- University of South Florida · 252 trials · 17% recruiting
- Boston Medical Center · 253 trials · 11% recruiting
- Shire · 245 trials · 0% recruiting
- University of Cincinnati · 245 trials · 14% recruiting
Sponsors near 14% open enrollment (± trial volume)
- ModernaTX · 14% recruiting · 90 trials
- The Cleveland Clinic · 14% recruiting · 688 trials
- University of Wisconsin, Madison · 15% recruiting · 1,039 trials
- Dana-Farber Cancer Institute · 14% recruiting · 781 trials
Related
What to do with this Masonic Cancer Center, University of Minnesota page
249 registered trials is a research-attention snapshot, not an endorsement of Masonic Cancer Center, University of Minnesota or any single study.
- 36 of Masonic Cancer Center, University of Minnesota's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition Masonic Cancer Center, University of Minnesota studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Masonic Cancer Center, University of Minnesota pipeline card: 249 registered trials from official public datasets.Report a data error.